In the news!
Press Releases
Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Betasarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E 150 150 Myonexus Therapeutics

Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Betasarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E

First-in-human trial of MYO-101 based on promising pre-clinical results offering the first corrective approach for LGMD2E NEW ALBANY, Ohio, November 8, 2018 — Myonexus Therapeutics, a clinical-stage gene therapy company developing first-ever corrective gene therapies for limb girdle muscular dystrophies (LGMD), in collaboration with Nationwide Children’s Hospital’s Center for Gene Therapy and Sarepta Therapeutics, announced…

read more
Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E 150 150 Myonexus Therapeutics

Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E

Rare Pediatric Disease Designation for MYO-101 Program Reflects Compelling Data and Enables Priority Review Voucher Eligibility NEW ALBANY, Ohio–(BUSINESS WIRE)–Myonexus Therapeutics, a clinical-stage gene therapy company developing first ever corrective gene therapies for limb girdle muscular dystrophies, and Nationwide Children’s Hospital announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric…

read more
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies 150 150 Myonexus Therapeutics

Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies

— Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise — — The program is designed, if successful, to offer first-ever corrective treatments for five distinct forms of Limb-girdle muscular dystrophy (LGMD) — — Sarepta is granted exclusive option to acquire Myonexus — CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company…

read more
Myonexus Therapeutics Secures $2.5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Therapies 150 150 Myonexus Therapeutics

Myonexus Therapeutics Secures $2.5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Therapies

MYO-101 Phase 1/2a systemic gene therapy trial for LGMD2E to begin in early 2018 NEW ALBANY, Ohio–(BUSINESS WIRE)–Myonexus Therapeutics, Inc. (Myonexus), a clinical-stage biotechnology company developing transformative gene therapies for limb-girdle muscular dystrophies (LGMDs), today announced the completion of a $2.5 million seed financing. The company is committed to accelerating development of five gene therapies…

read more
Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies 150 150 Myonexus Therapeutics

Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies

Innovative Gene Therapies with Potential to Become First-ever, Standard of Care Therapies for Limb-Girdle Muscular Dystrophies Announces Management Team of Industry Leaders with Technical and Commercial Expertise in Muscular Dystrophy Gene Therapy, Pharmaceuticals, and New Venture Development Licenses Innovative Gene Therapy Technologies from Nationwide Children’s Hospital, Columbus, Ohio Secures Initial Financing from Global Limb-Girdle Muscular…

read more